Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer, will engage in a fireside chat on Wednesday, December 4, 2024, from 2:30-2:55pm ET. The presentation will be accessible via live webcast through Inozyme's Investor Relations website section, with a replay available for time.

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).

Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.

For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com

Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com

FAQ

When is Inozyme Pharma (INZY) presenting at the Piper Sandler Healthcare Conference 2024?

Inozyme Pharma will present on Wednesday, December 4, 2024, from 2:30-2:55pm ET.

Who will represent Inozyme Pharma (INZY) at the Piper Sandler Healthcare Conference?

Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will represent the company.

How can investors watch Inozyme Pharma's (INZY) presentation at the Piper Sandler Conference?

Investors can access the live webcast through the Investor Relations section of Inozyme's website under events, where a replay will also be available.

What type of diseases does Inozyme Pharma (INZY) focus on developing treatments for?

Inozyme Pharma focuses on developing innovative therapeutics for rare diseases that affect bone health and blood vessel function.